eli lilly glp-1 receptor agonist products to seek approval of new weight-loss drug this year Eli Lilly releases topline data
Description
Acta Diabetol 60(9):12571266 [DOI] [PMC free article] [PubMed] [Google Scholar] 7.Berra C, Manfrini R, Bifari F, Cipponeri E, Ghelardi R, Centofanti L et al (2024) Improved glycemic and weight control with dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting
Convenient Weekly Dosing: Administered once per week, GLP-1 therapy is easier to manage than daily medications
doi: 10.2337/dc23-S002
It mimics a natural hormone in the body that is involved in the regulation of hunger, satiety, and blood sugar
